ArticleInternational journal of molecular sciences2025
Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer's Disease: A Fagan Nomogram-Based Meta-Analytic Study.Molecular neurobiology · 2026Pooled it
- Baseline plasma p-tau217/Aβ42 as a sensitive marker for the severity of Alzheimer's disease continuum.Journal of translational medicine · 2026Article
- Neuropathology and Biomarker Correlates of Late Onset Alzheimer's Disease in Aged Old World Monkeys.Toxicologic pathology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have demonstrated the high analytical and diagnostic performance of plasma p-tau217 using well-defined cohorts. We aimed to assess the analytical, diagnostic, and prognostic utility of plasma p-tau217 as a routine biomarker in symptomatic patients attending our memory clinic. We also sought to identify optimal cutoff points that align with cerebrospinal fluid (CSF) amyloid beta (Aβ) status. A total of 276 cognitively impaired patients were included, with 81 mild cognitive impairment (MCI) patients followed for a mean of 56 (±15.8) months to evaluate progression to Alzheimer's disease (AD). CSF and blood biomarkers of AD were quantified using the Lumipulse G platform. Plasma p-tau217 levels showed strong correlations with CSF Aβ42/Aβ40 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.